Related Experiment Videos
[Fibrinolysis: indications in ophthalmology]
1CHU, Sart-Tilman, Liège, Belgique.
Bulletin De La Societe Belge D'Ophtalmologie
|January 1, 1993
Summary
Microcatheter urokinase infusion offers a new therapy for central retinal artery occlusion, enabling in situ thrombolysis with fewer systemic side effects. Early treatment within hours of occlusion can lead to successful outcomes and improved vision.
Area of Science:
- Ophthalmology
- Vascular Medicine
- Interventional Radiology
Background:
- Central retinal artery occlusion (CRAO) is a leading cause of sudden, severe vision loss.
- Current treatments for CRAO have limited efficacy and significant risks.
- Systemic thrombolysis carries a high risk of hemorrhagic complications.
Purpose of the Study:
- To evaluate the efficacy and safety of microcatheter-guided urokinase infusion for in situ thrombolysis in CRAO.
- To determine the optimal timing for initiating this therapy to maximize visual recovery.
Main Methods:
- A microcatheter-based approach was used to deliver urokinase directly to the occluded central retinal artery.
- Treatment was initiated within the first few hours following the onset of CRAO symptoms.
- Visual acuity and funduscopic examinations were performed to assess treatment outcomes.
Main Results:
- Successful recanalization of the central retinal artery was achieved in a significant proportion of patients.
- Patients treated early demonstrated notable improvements in visual acuity.
- The localized infusion minimized systemic side effects commonly associated with thrombolytic therapy.
Conclusions:
- Microcatheter urokinase infusion represents a promising therapeutic strategy for acute central retinal artery occlusion.
- This localized approach offers a safer alternative to systemic thrombolysis, with potential for significant visual recovery.
- Timely intervention is crucial for achieving favorable outcomes in CRAO patients treated with this method.